225528-05-2

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 222854-50-4 (L)-4-iodophenylalanine t-butyl ester 
• 217326-47-1 4-iodo-(L)-phenylalanine, tert-butyl ester hydrochloride 

Downstream Products

• 474542-80-8 N-Fmoc-(L)-4-(2'-methoxy)biphenylalanine t-butyl ester 
• 225528-07-4 N-FMOC-(L)-4-trimethylstannylphenylalanine tert-butyl ester 
• 225528-11-0 Fmoc-4-(2-methoxyphenyl)-L-phenylalanine 

Relevant academic research and scientific papers

Substituted ureas as cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.

A series of potent N-(aralkyl-, arylcycloalkyl-, and heteroaryl-acyl)-4-biphenylalanine VLA-4 antagonists was prepared by rapid analogue methods using solid-phase chemistry. Further optimization led to several highly potent compounds (IC(50) 1 nM). Evalu